European Growth Companies With High Insider Ownership And Up To 58% Earnings Growth
In recent weeks, European markets have experienced volatility driven by escalating Middle East tensions and fluctuating energy prices, which have heightened inflation concerns and influenced investor sentiment. Despite these challenges, growth companies with high insider ownership continue to capture attention for their potential resilience and strong earnings prospects.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.8% |
| MilDef Group (OM:MILDEF) | 10.3% | 32.5% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 58.6% |
| KebNi (OM:KEBNI B) | 16.3% | 103.8% |
| Gold Road International (OB:GOLDR) | 35.9% | 89.8% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 41.1% |
| CD Projekt Red (WSE:CDR) | 35.2% | 53.9% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
| 2G Energy (XTRA:2GB) | 13.4% | 30% |
Let's uncover some gems from our specialized screener.
STIF Société anonyme (ENXTPA:ALSTI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: STIF Société anonyme manufactures and sells components for the handling of bulk products in France, with a market cap of €233.25 million.
Operations: The company's revenue segments consist of Handling Equipment (€19.60 million), Explosion Energy (BESS) (€41.40 million), US Distribution Segment (€4.40 million), Active Industry Explosion (€6.80 million), and Passive Industry Explosion (€16.60 million).
Insider Ownership: 11.6%
Earnings Growth Forecast: 17.2% p.a.
STIF Société anonyme is positioned for growth with forecasted revenue and earnings increases of 14.3% and 17.2% annually, outpacing the French market averages. Despite a high debt level, its price-to-earnings ratio of 19.8x offers value below the industry average of 24.9x. While insider buying data is unavailable, strong past earnings growth of 21.4% underscores its potential within Europe's landscape of companies with substantial insider ownership and growth prospects.
- Click here and access our complete growth analysis report to understand the dynamics of STIF Société anonyme.
- Upon reviewing our latest valuation report, STIF Société anonyme's share price might be too optimistic.
DNO (OB:DNO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DNO ASA is involved in the exploration, development, and production of oil and gas assets across the Middle East, the North Sea, and West Africa, with a market capitalization of NOK19.21 billion.
Operations: The company's revenue is primarily generated from its oil and gas activities, amounting to $2.42 billion.
Insider Ownership: 13.3%
Earnings Growth Forecast: 25.4% p.a.
DNO ASA has demonstrated strong earnings growth, recently becoming profitable with net income of US$134.1 million for the first half of 2026. Despite a forecasted revenue decline of 1.5% annually over the next three years, its earnings are expected to grow at 25.4% per year, surpassing the Norwegian market average. Insider buying has been substantial with no significant selling in recent months, indicating confidence in future performance despite dividends not being well-covered by earnings.
- Take a closer look at DNO's potential here in our earnings growth report.
- The valuation report we've compiled suggests that DNO's current price could be inflated.
Redcare Pharmacy (XTRA:RDC)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Redcare Pharmacy NV operates an online pharmacy business across the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France with a market cap of €1.22 billion.
Operations: The company's revenue is divided into two segments: DACH, generating €2.63 billion, and International, contributing €583.90 million.
Insider Ownership: 11.9%
Earnings Growth Forecast: 58.6% p.a.
Redcare Pharmacy is poised for growth, with revenue forecasted to increase at 10.5% annually, outpacing the German market's 6.7%. Despite recent volatility and a net loss of €5.8 million in H1 2026, earnings are expected to grow by 58.6% per year as the company aims for profitability within three years. Insider activity shows more buying than selling recently, reflecting confidence amid strategic advancements in digital healthcare solutions like PoPP and Health ID integration.
- Click here to discover the nuances of Redcare Pharmacy with our detailed analytical future growth report.
- Our comprehensive valuation report raises the possibility that Redcare Pharmacy is priced lower than what may be justified by its financials.
Next Steps
- Get an in-depth perspective on all 213 Fast Growing European Companies With High Insider Ownership by using our screener here.
- Seeking Other Investments? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com